Q-omics provides the consensus-scored ZXDC profile across patient tissues and cancer cell-line models. ZXDC expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ZXDC is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ZXDC RNA expression shows 20,643 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, HNSC, and ACC as cancer lineages where ZXDC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZXDC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZXDC survival associations across molecular data types. ZXDC RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZXDC RNA expression–survival associations across cancer types. High ZXDC expression shows unfavorable associations in LGG, LIHC and UCEC, but favorable associations in UCS, KIRC and SCLC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for ZXDC RNA expression.
This table summarizes ZXDC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZXDC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZXDC shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, COAD, LIHC and CHOL. The HNSC box plot shows higher ZXDC RNA expression in tumor versus normal tissue (log2 FC = +0.866, t-test p < 0.001).
This table shows molecular features associated with ZXDC in patient tissues and cancer cell lines. In patient samples, ZXDC shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZXDC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
